TY - JOUR
T1 - Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer
T2 - A systematic review and meta-analysis
AU - Buonerba, Carlo
AU - Ferro, Matteo
AU - Dolce, Pasquale
AU - Crocetto, Felice
AU - Verde, Antonio
AU - Lucarelli, Giuseppe
AU - Scafuri, Luca
AU - Facchini, Sergio
AU - Vaia, Angelo
AU - Marinelli, Alfredo
AU - Terracciano, Daniela
AU - Montella, Liliana
AU - Longo, Nicola
AU - Imbimbo, Ciro
AU - Mirone, Vincenzo
AU - Di Lorenzo, Giuseppe
AU - De Placido, Sabino
AU - Sonpavde, Guru
N1 - Publisher Copyright:
© 2020 Elsevier B.V.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/7
Y1 - 2020/7
N2 - Background: Both docetaxel and androgen-receptor-axis-targeted (ARAT) agents are approved in metastatic castration-sensitive prostate cancer (mCSPC) patients. Predictive factors of therapy efficacy are lacking. Methods: We included articles reporting data about randomized-controlled clinical trials (RCTs) testing an ARAT agent plus ADT vs. ADT. We aimed to obtain pooled estimates of efficacy outcomes and assess differences in pooled estimates of efficacy outcomes between sub-groups. Results: A total of 5427 mCSPC patients enrolled in five RCTs were evaluable for OS (Overall Survival) and PFS (Progression-free survival). Pooled OS-HR (Hazard Ratio) was 0.66 (95 % CI: 0.60−0.74), while pooled PFS-HR was 0.46 (95 % CI: 0.40−0.53). Combined treatment with docetaxel was associated with differential OS outcomes, while tumor volume according to the CHAARTED criteria and visceral metastasis were associated with differential PFS outcomes. Conclusion: Our results add evidence that ARAT agents improve OS in mCSPC and discourage their combined use with docetaxel in this setting.
AB - Background: Both docetaxel and androgen-receptor-axis-targeted (ARAT) agents are approved in metastatic castration-sensitive prostate cancer (mCSPC) patients. Predictive factors of therapy efficacy are lacking. Methods: We included articles reporting data about randomized-controlled clinical trials (RCTs) testing an ARAT agent plus ADT vs. ADT. We aimed to obtain pooled estimates of efficacy outcomes and assess differences in pooled estimates of efficacy outcomes between sub-groups. Results: A total of 5427 mCSPC patients enrolled in five RCTs were evaluable for OS (Overall Survival) and PFS (Progression-free survival). Pooled OS-HR (Hazard Ratio) was 0.66 (95 % CI: 0.60−0.74), while pooled PFS-HR was 0.46 (95 % CI: 0.40−0.53). Combined treatment with docetaxel was associated with differential OS outcomes, while tumor volume according to the CHAARTED criteria and visceral metastasis were associated with differential PFS outcomes. Conclusion: Our results add evidence that ARAT agents improve OS in mCSPC and discourage their combined use with docetaxel in this setting.
KW - Abiraterone
KW - Apalutamide
KW - Castration-sensitive prostate cancer
KW - Enzalutamide
UR - http://www.scopus.com/inward/record.url?scp=85085308126&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085308126&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2020.102992
DO - 10.1016/j.critrevonc.2020.102992
M3 - Review article
C2 - 32474391
AN - SCOPUS:85085308126
VL - 151
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
M1 - 102992
ER -